<code id='C2F42DBE62'></code><style id='C2F42DBE62'></style>
    • <acronym id='C2F42DBE62'></acronym>
      <center id='C2F42DBE62'><center id='C2F42DBE62'><tfoot id='C2F42DBE62'></tfoot></center><abbr id='C2F42DBE62'><dir id='C2F42DBE62'><tfoot id='C2F42DBE62'></tfoot><noframes id='C2F42DBE62'>

    • <optgroup id='C2F42DBE62'><strike id='C2F42DBE62'><sup id='C2F42DBE62'></sup></strike><code id='C2F42DBE62'></code></optgroup>
        1. <b id='C2F42DBE62'><label id='C2F42DBE62'><select id='C2F42DBE62'><dt id='C2F42DBE62'><span id='C2F42DBE62'></span></dt></select></label></b><u id='C2F42DBE62'></u>
          <i id='C2F42DBE62'><strike id='C2F42DBE62'><tt id='C2F42DBE62'><pre id='C2F42DBE62'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge